Related Experiment Videos
[Adoptive immunotherapy of malignant diseases using normal allogeneic LAK cells]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 1, 1987
Summary
Adoptive immunotherapy using allogeneic lymphokine-activated killer (LAK) cells shows promise for treating cancer. Patient plasma did not inhibit LAK cell activity, suggesting a lack of adverse immune reactions during therapy.
Area of Science:
- Immunology
- Oncology
- Cellular Therapy
Context:
- Adoptive immunotherapy is a promising approach for malignant diseases.
- Allogeneic lymphokine-activated killer (LAK) cells are derived from peripheral blood lymphocytes (PBL) of healthy donors.
- Potential for immune reactions against allogeneic LAK cells exists.
Purpose:
- To investigate the immune response to allogeneic LAK cells during adoptive immunotherapy.
- To assess the maintenance of LAK cell activity in the presence of patient plasma.
Summary:
- Allogeneic LAK cells were utilized for adoptive immunotherapy in patients with malignant diseases.
- Despite initial concerns, no adverse immune reactions were observed.
- LAK cell activity remained stable in vitro when exposed to patient plasma collected during therapy.
Impact:
- This study suggests that allogeneic LAK cell therapy is well-tolerated.
- The findings support the continued use of allogeneic LAK cells in cancer immunotherapy.
- Further research may explore the mechanisms preventing immune rejection of allogeneic LAK cells.